Cullinan Therapeutics, Inc. (CGEM) NASDAQ

Currency In USD

Key Executives

Name	Title	Pay	Year Born
Nadim Ahmed	President, Chief Executive Officer & Director	1.17M	1968
Patrick A. Baeuerle	Co-Founder, Chief Scientific Advisor & Chairman of Scientific Advisory Board	763,734	1958
Mary Kay Fenton	Chief Financial Officer	768,257	1964
Jeffrey Jones	Chief Medical Officer	801,783	1971
Nicholas Smith	Head of Investor Relations	0	N/A
Jacquelyn L. Sumer	Chief Legal Officer, Chief Compliance Officer & Corporate Secretary	0	1978
Rose Weldon	Senior Vice President of Corporate Affairs	0	N/A
Corinne Savill	Chief Business Officer	0	1959
Jennifer Michaelson	Chief Scientific Officer	0	1967
Steve Andre	Chief Human Resources Officer	0	N/A

Name

Title

Pay

Year Born

Nadim Ahmed

President, Chief Executive Officer & Director

1.17M

1968

Patrick A. Baeuerle

Co-Founder, Chief Scientific Advisor & Chairman of Scientific Advisory Board

763,734

1958

Mary Kay Fenton

Chief Financial Officer

768,257

1964

Jeffrey Jones

Chief Medical Officer

801,783

1971

Nicholas Smith

Head of Investor Relations

N/A

Jacquelyn L. Sumer

Chief Legal Officer, Chief Compliance Officer & Corporate Secretary

1978

Rose Weldon

Senior Vice President of Corporate Affairs

N/A

Corinne Savill

Chief Business Officer

1959

Jennifer Michaelson

Chief Scientific Officer

1967

Steve Andre

Chief Human Resources Officer

N/A

Description

Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysplastic syndrome. The company is also developing Zipalertinib, an orally available small-molecule, irreversible epidermal growth factor receptor inhibitor in Phase 2b portion of the REZILIENT1 clinical trial in patients with EGFR ex20ins non-small cell lung cancer. It has a license agreement with Chongqing Genrix Biopharmaceutical Co., Ltd to develop and commercialize velinotamig; a co-development agreement with Taiho Pharmaceutical Co., Ltd to develop zipalertinib; and a collaboration agreement with Adimab, LLC to discover and/or optimize antibodies. The company was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.